The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does cytogenetic risk affect outcome of allo-SCT in patients with FLT3+ NPM1– AML?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How does cytogenetic risk affect outcome of allo-SCT in patients with FLT3+ NPM1– AML?

How does cytogenetic risk affect outcome of allo-SCT in patients with FLT3+ NPM1– AML?

Nagler discusses how the addition of cytogenetic risk classification (low, intermediate, and high) to mutation phenotype (FLT3+ NPM1–) affects prognosis for allogeneic stem cell transplantation (allo-SCT) in patients with AML. He also discusses the prognostic factor of measurable residual disease (MRD) in combination with cytogenetic risk in the pre-transplant setting.

 

Share: